Drug intelligence / Profile preview

TrastuRel

Development stage: Phase 3
Lead developer: Reliance Life Sciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

TrastuRel is a biosimilar version of trastuzumab, a humanized IgG1 kappa recombinant monoclonal antibody developed and marketed by Reliance Life Sciences. It selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 (HER2) protein. By inhibiting HER2, the drug disrupts downstream signaling pathways that drive tumor cell proliferation and survival. Additionally, it mediates antibody-dependent cellular cytotoxicity (ADCC), leading to the destruction of HER2-overexpressing cancer cells. TrastuRel is approved for the treatment of HER2-positive breast cancer and HER2-positive gastric (stomach) cancer, and is available in both intravenous and subcutaneous formulations.

Brand names: TrastuRel
Other names: trastuzumab

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on TrastuRel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TrastuRel.

Explore the full profile